The economic impact of depression: Resistance or severity?

European Neuropsychopharmacology

Volumn 20, Issue 10, 2010, Pages 671-675

  Fostick, L ^a   Silberman, A ^b   Beckman, M ^c   Spivak, B ^c   Amital, D ^c  

^a ARIEL UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c NESS ZIONA MENTAL HEALTH CENTER   (Israel)

Author keywords

Economic burden; Major Depressive Disorder (MDD); Severity; Treatment Resistant Depression (TRD)

Indexed keywords

ADULT; ARTICLE; DISEASE SEVERITY; FEMALE; HAMILTON SCALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; COST OF ILLNESS; DEPRESSIVE DISORDER, MAJOR; DISEASE PROGRESSION; DRUG RESISTANCE; FEMALE; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX;

EID: 77956179547     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.06.001     Document Type: Article

References (24)

1. Monthly Average Wage per Employee Job in 2005. Central Bureau of Statistics, press release no. 47/2006, March 8, 2006.
2. Corey-Lisle P.K., Birnbaum H.G., Greenberg P.E., Marynchenko M.B., Claxton A.J. Identification of a claims data "signature" and economic consequences for treatment-resistant depression. J. Clin. Psychiatry 2002, 63(8):717-726.
3. Crown W.H., Finkelstein S., Berndt E.R., Ling D., Poret A.W., Rush A.J., Russell J.M. The impact of treatment-resistant depression on health care utilization and costs. Clin. Psychiatry 2002, 63(11):963-971.
4. Fava M. Diagnosis and definition of treatment-resistant depression. Biol. Psychiatry 2003, 15(53(8)):649-659.
5. Fredman S.J., Fava M., Kienke A.S., White C.N., Nierenberg A.A., Rosenbaum J.F. Partial response, non-response, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. J. Clin. Psychiatry 2000, 61(6):403-408.
6. Greenberg P.E., Stiglin L.E., Finkelstein S.N., Berndt E.R. The economic burden of depression in 1990. J. Clin. Psychiatry 1993, 54(11):405-418.
7. Greenberg P.E., Kessler R.C., Birnbaum H.G., Leong S.A., Lowe S.W., Berglund P.A., Corey-Lisle P.K. The economic burden of depression in the United States: how did it change between 1990 and 2000?. J. Clin. Psychiatry 2003, 64(12):1465-1475.
8. Greenberg P., Corey-Lisle P.K., Birnbaum H., Marynchenko M., Claxton A. Economic implications of treatment-resistant depression among employees. Pharmacoeconomics 2004, 22(6):363-373.
9. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23:56-62.
10. Joyce P.R., Mulder R.T., Luty S.E., McKenzie J.M., Sullivan P.F., Abbott R.M., Stevens I.F. Melancholia: definitions, risk factors, personality, neuroendocrine markers and differential antidepressant response. Aust. N. Z. J. Psychiatry 2002, 36(3):376-383.
11. Kessler R.C., Borges G., Walters E.E. Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey. Arch. Gen. Psychiatry 1999, 56(7):617-626.
12. Kind P., Sorensen J. The costs of depression. Int. Clin. Psychopharmacol. 1993, 7(3-4):191-195.
13. Kocsis J.H. New strategies for treating chronic depression. J. Clin. Psychiatry 2000, 61(Suppl 11):42-45.
14. Ministry of Health published price list for ambulatory utilization and differential procedures, 2006.
15. Nemeroff C.B. Prevalence and management of treatment-resistant depression. J. Clin. Psychiatry 2007, 68(Suppl 8):17-25.
16. Russell J.M., Hawkins K., Ozminkowski R.J., Orsini L., Crown W.H., Kennedy S., Finkelstein S., Berndt E., Rush A.J. The cost consequences of treatment-resistant depression. J. Clin. Psychiatry 2004, 65(3):341-347.
17. Sackeim H.A. The definition and meaning of treatment-resistant depression. J. Clin. Psychiatry 2001, 62(Suppl 16):10-17.
18. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl 20):22-33.
19. Souery D., Amsterdam J., de Montigny C., Lecrubier Y., Montgomery S., Lipp O., Racagni G., Zohar J., Mendlewicz J. Treatment-resistant depression: methodological overview and operational criteria. Eur. Neuropsychopharmacol. 1999, 9(1-2):83-91.
20. Souery D., Oswald P., Massat I., Bailer U., Bollen J., Demyttenaere K., Kasper S., Lecrubier Y., Montgomery S., Serretti A., Zohar J., Mendlewicz J. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J. Clin. Psychiatry 2007, 68(7):1062-1070.
21. Stewart W.F., Ricci J.A., Chee E., Hahn S.R., Morganstein D. Cost of lost productive work time among US workers with depression. JAMA 2003, 289(23):3135-3144.
22. Thase M.E., Rush A.J. When at first you don't succeed: sequential strategies for antidepressant non-responders. J. Clin. Psychiatry 1997, 58(Suppl 13):23-29.
23. Thomas C.M., Morris S. Cost of depression among adults in England in 2000. Br. J. Psychiatry 2003, 183:514-519.
24. Tierney J.G. Treatment-resistant depression: managed care considerations. J. Manag. Care Pharm. 2007, 13(6 Suppl A):S2-S7.